The Pulse
China accepts application for Harbour BioMed's AI-enabled drug
China's drug regulator has accepted Harbour BioMed's investigational new drug application for LET003, a candidate for overweight or obesity. The company previously reported results from preclinical animal studies of the antibody, including tests in combination with semaglutide.

China's drug regulator has accepted an investigational new drug application for LET003, Harbour BioMed's first AI-enabled drug candidate, which is being developed for overweight or obesity. The company said on Nov. 18 that the National Medical Products Administration had accepted the application for the antibody.
LET003 is designed to block the activin receptors ACVR2A and ACVR2B, which help regulate muscle and fat. The company used its Hu-mAtrIx artificial intelligence platform in developing the candidate.
Preclinical results
In May, Harbour BioMed reported animal studies examining LET003 on its own and in combination with semaglutide. The company said the combination increased fat reduction while mitigating lean mass loss compared with semaglutide alone.
In an obesity model using wild-type mice, researchers administered semaglutide at 30 nmol/kg and LET003 at 20 mg/kg under the skin once a week, either separately or together. After three weeks, the combination group had 76.0% less fat mass than the vehicle group and 34.7% less than the semaglutide-only group, according to the company's results.
Lean mass in the combination group was 6.5% lower than in the vehicle group but 5.7% higher than in the semaglutide-only group. The company presented the findings as evidence that the combination could reduce fat while mitigating lean mass loss associated with semaglutide treatment alone.
Further mouse comparisons
A separate experiment used human FcRn transgenic mice with obesity induced by a high-fat diet. After three weeks of weekly treatment at the same doses, the combination group's fat-to-body weight ratio was 17.5% lower than the vehicle group's and 6.0% lower than the semaglutide-only group's, Harbour BioMed reported.
The lean mass-to-body weight ratio was 15.2% higher than with vehicle and 5.3% higher than with semaglutide alone. Both comparisons were made in the mouse model.
Another study compared LET003 with bimagrumab in human FcRn transgenic mice maintained on a normal diet. After three weeks, LET003 at 5 mg/kg produced lean mass-promoting effects comparable to those observed with bimagrumab at 15 mg/kg, the company said.
The company also reported that LET003 cleared from the blood more slowly than all comparator molecules tested in human FcRn transgenic mouse and cynomolgus monkey models. The comparison followed administration under the skin.
AI platform
Harbour BioMed used structural biology and AI-driven antibody engineering in developing LET003. Founder, chairman and CEO Jingsong Wang said in the earlier announcement that Hu-mAtrIx uses data from the company's Harbour Mice platforms and combines fine-tuned large language models for sequence generation with AI classification and developability prediction models.
In the latest announcement, Wang said the company looked forward to advancing the candidate through clinical development. Bob Zhang, president of Harbour BioMed's metabolic disease franchise, said the company also looked forward to evaluating the candidate's potential in clinical development.
Sources
- Original source · Press release Harbour BioMed via PR Newswire prnewswire.com
Other pages read
- Harbour BioMed harbourbiomed.com
Related stories
- European Commission says AI-linked cyber campaign hit its systems
- Nieman Lab: McClatchy plans AI overhaul after local newspaper layoffs
- Aikido finds reachable secrets in 13 of 50 AI security incidents
- Cegedim opens French data center for AI and high-density computing
- Researcher says CreditNirvana flaws exposed 6.6 million accounts